Summary: Recent approvals of PARP inhibitors mark the beginning of precision medicine for prostate cancer. Through patient case scenarios, Drs. Lisa Holle (Oncology Pharmacist, Univ. of Connecticut) and Pedro C. Barata (Medical Oncologist, Tulane Univ.) dive in-depth into appropriate use of olaparib and rucaparib in clinical practice, including patient and disease factors. If you liked this episode, please subscribe. Learn more at https://elearning.asco.org, or email us at: education@asco.org
